Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland.
about
Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis.Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature.A multimodal approach to the management of neuroendocrine tumour liver metastasesInduction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in a Murine Model of a Human Neuroendocrine Tumor.Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies.Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation studyTreatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy.Role of surgery and transplantation in the treatment of hepatic metastases from neuroendocrine tumor.Use of radioactive substances in diagnosis and treatment of neuroendocrine tumorsDiagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art.In vivo evaluation of PEGylated ⁶⁴Cu-liposomes with theranostic and radiotherapeutic potential using micro PET/CT.Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.The safety of available treatments options for neuroendocrine tumors.Neodymium-140 DOTA-LM3: Evaluation of an In Vivo Generator for PET with a Non-Internalizing VectorSpecific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors.The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors.Evaluation of the Possible Utilization of 68Ga-DOTATOC in Diagnosis of Adenocarcinoma Breast Cancer.Long-term results and tolerability of tandem peptide receptor radionuclide therapy with 90Y/177Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study.How smart is peptide receptor radionuclide therapy of neuroendocrine tumors especially in the salvage setting? The clinician's perspective.Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE.SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors.Incidence and survival of patients with small intestinal neuroendocrine tumours in a Danish NET center.Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and mythsENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues
P2860
Q33700134-96002208-448C-40D1-A63D-44F03AD3F8CDQ33737587-98768D8F-CDF9-4934-A622-F26C9622EFBBQ35810562-F722822F-B1C8-40B4-99A2-44089F04F6F1Q36335128-2D513E6A-A941-4336-A96F-CE151A65F8A0Q36512778-2243B02E-4F97-4161-B98B-1281CD891D01Q36516035-E7E59267-14FD-4083-9B59-145B0286CEABQ36578624-C198AED5-3FBB-4B22-9FFD-06F081920085Q37975101-E98EB850-629B-4E80-89DF-CDF5DE2E629DQ38262113-EB509D18-3EEB-404D-843B-ECFADFC6E90CQ38469898-6908CBCD-9309-432B-B9D3-4A87DBDD75B2Q38557054-52E2D846-722B-4D38-85C4-4B4B6C9D8BC0Q38813559-17DDA47A-65C7-485C-8FD1-761FCF354628Q38909078-8D3912D4-B7CF-445E-A0B5-A8ADABBB28EEQ39433254-CADC7704-1EA1-44C0-9833-A1593C30010EQ40986557-AF97E5DC-7AE3-4F9D-AE16-B1ECB5775AC5Q41161125-3ECC942F-55F3-42C2-A2A0-BA9301F729E3Q41244010-4862251A-615C-4E71-9E35-B1F26B4F66E4Q47589004-B5FF66D0-89B3-474F-886B-B814F47E103FQ50049100-494F8AA0-20C0-42B1-B08D-3CB429EBD5E9Q50790805-ABE75D68-80CD-47C5-92DD-2C4CCF60AC5FQ52881909-8327D16F-6095-42C4-998E-0F6BDFF00ED4Q52964782-099A1C62-A5D6-4CED-8B73-98851B949607Q53045254-E340B306-8FB2-4549-914A-8E5C11723C99Q55395373-58D533A7-4A21-4EFA-9030-310DBB8F1EDFQ56962802-3782CBA0-282A-4BFB-89CA-31622EB85752Q57990732-6919F090-7BFC-40E0-98FD-40A5B4980397
P2860
Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Peptide receptor radionuclide ...... cohort treated in Switzerland.
@en
Peptide receptor radionuclide therapy with Y-DOTATOC and
@nl
type
label
Peptide receptor radionuclide ...... cohort treated in Switzerland.
@en
Peptide receptor radionuclide therapy with Y-DOTATOC and
@nl
prefLabel
Peptide receptor radionuclide ...... cohort treated in Switzerland.
@en
Peptide receptor radionuclide therapy with Y-DOTATOC and
@nl
P2093
P50
P356
P1433
P1476
Peptide receptor radionuclide ...... cohort treated in Switzerland.
@en
P2093
Andreas Klaus Pfeifer
Carsten Palnæs Hansen
Jan Müller-Brand
Karin Herskind Bruun
Klaus Krogh
Ulrich Knigge
P304
P356
10.1159/000324096
P577
2011-02-19T00:00:00Z